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No effect of dose, hepatic function, or nutritional status on 5-FU
clearance following continuous (5-day), 5-FU infusion
R.A. Fleming*, G.A. Milano, M.-C. Etienne, N. Renee, A. Thyss, M. Schneider & F. Demard
Laboratoire d'Oncopharmacologie, Centre Antoine-Lacassagne, Nice, France.
Summary One hundred and eighty seven patients (155 males, 32 females) with histologically proven and
previously untreated head and neck cancer were entered in the study. A total of 222 cycles of therapy were
analyzed (cisplatin 100 mg m-2 on day I and 5-day continuous intravenous infusion of 5-FU
550-1069 mg m-2 day-', mean 875.5 mgm-2 day-'). Significant interpatient variability for various 5-FU
pharmacokinetic parameters was observed including an almost ten-fold range in 5-FU clearance (5-FU Cl,
ml min-m-2 = 791-7769, mean 2820.7). Log 5-FU Cl was not modified by 5-FU dose (r = - 0.1034,
P = 0.124, n = 222). Poor linear correlations between log 5-FU Cl and hepatic function tests were observed
(respective r and P values for 222 cycles, log AST:0.0526, 0.4365; Log ALT: - 0.1167, 0.0842; Log AIK.
Phos.:0.154, 0.0214; Log GGT: 0.0652, 0.3436; Log LDH: - 0.0984, 0.1563; Log bilirubin: 0.1278, 0.0601).
The log 5-FU Cl was also poorly correlated with the serum concentration of various nutritional proteins
(respective r and P values for 222 cycles, Albumin: 0.0110, 0.8714; prealbumin: - 0.1067, 0.1129; transferrin:
0.0439, 0.5226). Laboratory data including indices of hepatic function and nutritional status cannot account
for the interpatient variability in 5-FU disposition.
Despite its use for over three decades, fluorouracil (5-FU)
remains one of the most commonly administered anticancer
agents. 5-FU is currently used in the initial treatment of
digestive, head and neck, and breast cancer. New discoveries
of synergistic drug combinations (interferon) and methods of
biochemical modulation continue to enhance the therapeutic
efficacy of 5-FU (Grem, 1990).
Several studies have reported the pharmacokinetics of
5-FU following continuous intravenous administration
(Floyd et al., 1982; Thyss et al., 1986a; Erlichman et al.,
1986). In these studies, wide interpatient variability in the
disposition of 5-FU has been described. Variability in the
pharmacokinetics of 5-FU is clinically significant since
numerous studies have reported relationships between 5-FU
pharmacokinetics and various indices of patients toxicity
(Thyss et al., 1986a; Goldberg et al., 1988; Au et al., 1982;
Trump et al., 1991; Santini et al., 1989). We recently prospec-
tively validated our prior model for the relationship between
5-FU AUC and toxicity: the AUC was estimated midway
through a 5-day course and the dose adjusted to produce a
target AUC; this resulted in a decrease in the incidence of
toxicity without change in the response rate, compared with
historical controls (Santini et al., 1989).
Despite numerous pharmacokinetic studies of 5-FU, little
is known concerning factors which affect 5-FU pharmaco-
kinetics following continuous infusion therapy. Several stu-
dies following intravenous bolus or oral administration of
5-FU have suggested the systemic clearance of 5-FU is
saturable (nonlinear) with increasing 5-FU dose (Christo-
phidis et al., 1978; McDermott et al., 1982; Collins et al.,
1980). In contrast, steady-state concentrations of 5-FU have
been observed to increase linearly with dose following con-
tinuously administered 5-FU (Erlichman et al., 1986). The
majority of an administered 5-FU dose (>80%) is catabo-
lised by dihydropyrimidine dehydrogenase (DPD), whose
greatest activity is found in the liver (Diasio & Harris, 1989).
The nonlinearity of 5-FU pharmacokinetics following bolus
administration is due to saturation of DPD (McDermott et
al., 1982). Since the majority of DPD activity is in the liver,
it is of concern if liver dysfunction alters the disposition of
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5-FU. Several studies (Floyd et al., 1982; Christophidis et al.,
1978; Ensminger et al., 1978; Nowakowska-Dulawa, 1990)
have determined the pharmacokinetics of 5-FU in the pre-
sence of liver dysfunction but it is unclear if the phar-
macokinetics of 5-FU are altered and if these alterations
require reduction of drug dose.
The pharmacokinetics of several drugs are altered in
patients with poor nutritional status (Krishnaswamy, 1978).
Cancer patients, especially with head and neck cancer and
digestive cancer, may be of poor nutritional status due to
difficulty in eating, toxicity to treatment (nausea and vomi-
ting), tumour-induced cachexia or a combination of these
problems. Since the therapeutic range of anticancer agents is
believed to be narrow, alterations in the pharmacokinetics of
anticancer agents due to poor nutritional status may cause
increased toxicity. Since 5-FU is increasingly administered as
initial therapy for patients with head and neck cancer (Thyss
et al., 1986b; Amrein & Weitzman, 1985; Kish et al., 1982)
and in adjuvant therapy for digestive tract cancer, it is
important to determine if nutritional status alters the disposi-
tion of 5-FU.
The purpose of this study was to determine the influence of
5-FU dose, hepatic function, and nutritional status on the
pharmacokinetics of 5-FU following continuous intravenous
administration in 187 patients with head and neck cancer.
Materials and methods
Patient characteristics and treatment regimen
We routinely monitor plasma 5-FU concentrations since we
have demonstrated the therapeutic index of 5-FU can be
improved by adjusting 5-FU doses based on 5-FU phar-
macokinetic data (Santini et al., 1989). Patients having been
treated between January 1988 and January 1990 with plasma
5-FU pharmacokinetic data were included in the study. One
hundred and eighty-seven patients (155 males, 32 females)
with histologically proven and previously untreated head and
neck cancer were entered in the study. Only treatment cycles
where hepatic function tests and serum protein concentra-
tions were determined (see below) were included in the
analysis. In the majority of patients, only the first cycle of
5-FU therapy was analysed. The interval between cycles was
3 weeks. Three successive cycles of therapy were planned for
each patient. The median age of the patients was 62.0-years-
old (range 35-85). Hematologic tests (complete blood
count), hepatic function tests (AST, ALT, alkaline phos-
phatase, GGT, LDH, and bilirubin), and renal function tests
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were performed prior to receiving therapy and during the
treatment course. Serum proteins (albumin, transferrin, and
prealbumin) were also determined and used as markers of
nutritional status. Hematologic tests, hepatic function tests,
and serum protein concentrations were determined within 1
week (typically the day prior) of the initiation of cytotoxic
chemotherapy. On day 1, all patients received cisplatin
100 mg m2 by intravenous infusion followed by 5-FU at
starting doses of 550-1069 mg m-2 day-' (mean = 875.5
mg m2 day-') on days 2-6 administered by controlled flow
pump. Starting doses varied as a function ofpatients age and
performance status. 5-FU doses were routinely adjusted at
midcycle (according to the midcycle AUC) to achieve a
targeted systemic exposure (Santini et al., 1989). A total of
222 cycles were available for this multiparametric analysis.
Sample collection and assay methodology
Blood samples (5 ml) were collected during 5-FU administra-
tion at 08:00 and 17:00 h. The samples were immediately
centrifuged (10 min, 2500 r.p.m.) and the plasma stored at
- 20C until analysed. Plasma 5-FU concentrations were
determined by a HPLC method (Christophidis et al., 1979).
The limit of sensitivity for 5-FU was 10ngml-'. The intra-
and interday coefficients of variation for 5-FU were < 10%.
Pharmacokinetic analysis
The 5-FU AUC was determined by the logarithmic trap-
ezoidal method from 0 to 48 h (midcycle) (Yeh & Kwan,
1978). Systemic clearance was calculated by dividing the total
dose administered during 48 h by the AUC (0-48 h) (Gibaldi
& Perrier, 1982).
Statistical analysis
The normality of all pharmacokinetic and biochemical para-
meters was assessed by Chi-square analysis. For normally
distributed data, the mean ± standard deviation (s.d.) is
reported. Data not being normally distributed was trans-
formed to the logarithm of its respective value. Relationships
between various biochemical parameters (hepatic function
tests and serum proteins) and 5-FU clearance were assessed
by both simple linear and stepwise, multiple regression
analysis. The a priori level of significance was set at P<0.05.
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Results
A total of 187 patients (222 cycles) were analysed. Significant
interpatient variability for various 5-FU pharmacokinetic
parameters was observed (Table I), including an almost ten-
fold range in 5-FU clearance. The frequency distribution for
5-FU clearance (222 cycles) is shown in Figure 1. There was
a significant relationship between 5-FU dose and the AUC
0-48 h (r = 0.4433, P<0.00001). Conversely 5-FU clearance
(i.e. log clearance) was not modified by 5-FU dose (r =
- 0.1034, P = 0.124, Figure 2) suggesting that at the doses
evaluated there was no evidence of diminished 5-FU clear-
ance with increased doses.
Significant interpatient variability in hepatic function and
plasma nutritional protein concentrations was observed in
our patient population (Table II). The results from simple
linear regression analysis of various hepatic function tests
versus log 5-FU clearance are shown in Table III. Poor linear
correlations between log 5-FU clearance and hepatic function
tests were observed. The log 5-FU clearance was poorly
correlated with the serum concentration of various proteins
which served as markers of nutritional status (Table IV).
Attempts at correlating several hepatic or nutritional
parameters with the variability of log 5-FU clearance by
stepwise, multiple regression analysis were unsuccessful in
identifying a statistically significant linear model.
Discussion
Considering the specific objectives of the present study, we
attempted to limit potential sources of uncontrolled inter-
patient variability by including patients with the same local-
isation ofdisease, all patients being previously untreated, and
all patients receiving the same chemotherapy treatment pro-
Table I Summary ofpharmacokinetic parameters
Parameter Mean ± s.d. Range
Dose 875.5± 136.6 552-1069
(mg m-2)
5-FUAUCo 48h 11921.7 ± 5325.4 3600-41095
(ng ml-' x h)
5-FU Cl 2820.7 ± 1053.3 791 -7769
(ml min- I m-2)
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5-FU systemic clearance (ml min-' m-2)
Figure 1 Histogram distribution of 5-FU clearance in the studied population.
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Figure 2 Scattergram for the evolution of log 5-FU clearance as a function of the dose.
Table II Summary oflaboratory parameters
Parameter' Mean + s.d. Range
Serum creatinine 9.5 ± 2.5 5.5-21
(< 12 mg -')
AST 17.5± 10.9 5-86
(<25 IU 1-1)
ALT 15.9± 16.1 4-189
(<30 IU 1- )
Alkaline phosphatase 144.5 ± 103.2 15-1068
(<210 IU 1-')
GGT 52.8 76.1 4-491
(<37 IU 1-)
LDH 228.4 93.0 80-1190
(<330 IU 1-')
Bilirubin 6.7 ± 3.5 2-28
(< 17 mg1-')
Albumin 38.2 ± 6.0 18-55
(32-45 g I-')
Prealbumin 0.25 ± 0.07 0.04-0.53
(0.17 -0.40gdl')
Transferrin 2.76 ± 0.56 1.59-4.39
(2.0-4.0 gdl-')
'Values inparentheses notenormal values.
Table III Results of simple linear regression analysis of hepatic
parameters versus log 5-FU Cl
Parameter r P
LogAST - 0.0526 0.4365
LogALT -0.1167 0.0842
LogAlk. Phosp. 0.154 0.0214
LogGGT 0.0652 0.3436
Log LDH -0.0984 0.1563
Log Bilirubin - 0.1278 0.0601
Table IV Results of simple linear regression of various plasma
nutritional proteins versus log 5-FU Cl
Parameter r P
Albumin 0.0110 0.8714
Prealbumin - 0.1067 0.1129
Transferrin 0.0439 0.5226
tocol. The pharmacokinetic parameters observed in our large
set of patients are similar to those reported by other inves-
tigators following continuous intravenous infusion of 5-FU
(Floyd et al., 1982; Thyss et al., 1986a; Erlichman et al.,
1986). The median value for 5-FU clearance (2664 ml
min-m M2) was significantly greater than liver blood flow
suggesting that catabolism in other tissues contributes
significantly to 5-FU degradation. In this studied population,
there were patients with particularly high mid-cycle AUC (up
to 41095 mg ml' x h) being at high risk of toxicity and
necessitating dose reduction (Santini et al., 1989). As re-
ported previously, there was a significant relationship noted
between the 5-FU dose and AUC (Milano et al., 1988).
Several studies have reported the pharmacokinetics of 5-FU
to be nonlinear with increasing 5-FU dose (Christophidis et
al., 1978; McDermott et al., 1982; Collins et al., 1980). As
reported by others (Erlichman et al., 1986), we found the
pharmacokinetics of 5-FU following continuous infusion to
be linear and clearance to be unchanged with increased 5-FU
doses within a 2 fold range (550-1069 mg m2day-' x 5).
This has practical consequences since this observation implies
that dose modification of 5-FU administered by continuous
intravenous results in proportional changes in total body
drug exposure.
Since 5-FU is believed to be extensively catabolised by the
liver, it is of concern whether 5-FU doses should be reduced
in the presence of hepatic dysfunction. Christophidis and
coworkers (1978) were unable to relate bioavailability of
5-FU to various hepatic function tests or to the presence of
hepatic metastases. Floyd and associates (1982) reported the
clearance of 5-FU to be altered in the presence of hepatic
metastases although other studies (Nowakowska-Dulawa,
1990) have found no effect of liver metastases on 5-FU
disposition. Traditional tests of hepatic function may not
reflect the drug metabolic capabilities of the liver. To assess
hepatic oxidative function, investigators have utilised drugs
such as antipyrine. Due to the heterogeneity of the cyto-
chrome P-450 system, antipyrine only provides a qualitative
reflection of hepatic oxidative function (Vesell, 1991). Since
DPD is primarily a cytosolic rather than a microsomal
enzyme, it is unlikely that markers such as antipyrine would
be useful in predicting 5-FU clearance. We have recently
reported a significant relationship (Fleming et al., 1991)
between DPD activity in mononuclear cells and 5-FU clear-
ance (r = 0.716, P<0.0001). Despite its potential utility in
patients with normal organ function, knowledge of lym-
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phocyte DPD activity is probably not of benefit in patients
with severe hepatic dysfunction. Our population of patients
was well suited for evaluating She influence of hepatic dys-
function of 5-FU as observed by the wide variability of
hepatic function tests. However serum bilirubin was not
significantly elevated in the majority of our patients (upper
range 28 mg 1'). Given that the majority of our patients had
mild to moderate hepatic dysfunction, additional studies in
patients with severe dysfunction are necessary. We observed
poor correlations between various hepatic function tests and
5-FU clearance. Since only 12% of patients with head and
neck cancer have distant metastases to organs (Merino et al.,
1977) including the liver, our population may not reflect
what may occur in other populations where liver metastases
is more common (digestive cancer, breast cancer). Because
pharmacodynamic endpoints (mucositis, leukopenia) were
not compared between patients with normal liver function
and hepatic dysfunction, we consider that additional studies
are necessary to determine if the severity of 5-FU-induced
toxicities is different in patients with normal and abnormal
hepatic function. There were 21 patients followed for more
than one cycle of 5-FU (18 patients with cycle I and cycle 2,
3 patients with cycle 1, cycle 2 and cycle 3). In examination
of the data for these 21 patients, it did not appear that 5-FU
clearance consistently increased or decreased from cycle to
cycle (NS, Wilcoxon signed rank test); considering the var-
ious hepatic function tests there was a significant reduction in
the levels of GGT, alkaline phosphatase and ALT; for the
other hepatic function tests there were no significant changes
(Wilcoxon signed rank test).
Nutritional status, especially in malnourished patients can
influence the metabolism of drugs (Krishnaswamy, 1978),
including the disposition of anticancer drugs (Mihranian et
al., 1984). A recent study (Davis et al., 1990) reported that
rats with protein-calorie malnutrition had significantly de-
creased 5-FU clearance as compared to rats with normal
nutritional status. Our population (head and neck cancer
patients) was well suited to evaluate the effect of nutritional
status on the disposition of 5-FU. We observed a wide range
of nutritional status as reflected by the wide dispersion of
visceral protein data. Visceral proteins thought to be most
relevant for evaluating nutritional status include albumin,
transferrin, and prealbumin (Teasley, 1989). We have pre-
viously demonstrated serum prealbumin to reflect the nutri-
tional status of cancer patients (Milano et al., 1978). Based
on the findings in our study, nutritional status does not
influence the clearance of 5-FU. Since toxicities (mucositis,
leukopenia) were not assessed in our study, additional studies
are needed to determine if malnourished patients for other
reasons than pharmacokinetic considerations may have
significantly increased toxicity following 5-FU administration
as compared to patients of normal nutritional status.
In conclusion, we found 5-FU clearance to be unaffected
by dose, hepatic function, or nutritional status. Laboratory
data including indices of hepatic function and nutritional
status does not appear useful in identifying individuals at risk
for altered 5-FU clearance. From a practical point of view
and based on pharmacokinetic considerations, dose reduc-
tions of 5-FU are not indicated in the presence of mild to
moderate hepatic dysfunction or altered nutritional status.
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